311690 — CJ Bioscience Income Statement
0.000.00%
Last trade - 00:00
- KR₩106bn
- KR₩66bn
- KR₩6bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,783 | 5,312 | 4,363 | 4,075 | 5,575 |
Cost of Revenue | |||||
Gross Profit | 2,673 | 2,415 | 1,653 | 1,406 | 1,843 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 9,302 | 13,825 | 16,606 | 37,308 | 37,556 |
Operating Profit | -4,519 | -8,513 | -12,243 | -33,233 | -31,981 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4,346 | -8,763 | -19,272 | -34,913 | -22,913 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4,346 | -8,763 | -19,272 | -34,913 | -22,913 |
Net Income Before Extraordinary Items | |||||
Net Income | -4,346 | -8,763 | -19,272 | -34,913 | -22,913 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -4,346 | -8,763 | -19,272 | -34,913 | -22,913 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1,130 | -1,928 | -3,459 | -5,040 | -3,245 |
Dividends per Share |